11/19/2026 | Press release | Distributed by Public on 11/19/2026 15:52
Filed Pursuant to Rule 433 under the Securities Act of 1933
Registration Statement No. 333-285032
Issuer Free Writing Prospectus, dated November 19, 2026
American Medical Systems Europe B.V.
€4,250,000,000
Senior Notes Offering
Terms and Conditions - 2-YearFloating Rate Notes (the "Floating Rate Notes")
| Issuer | American Medical Systems Europe B.V. (the "Issuer") |
| Guarantor | Boston Scientific Corporation ("Boston Scientific") |
| Note Type | Senior Notes |
| Form of Offering | SEC Registered |
|
Issuer Ratings (M/S&P/F)1 |
A3 / A- / A- (Negative/Negative/Stable) |
|
Expected Ratings (M/S&P/F)1 |
A3 / A- / A- |
| Principal Amount | €500,000,000 |
| Trade Date | November 19, 2026 |
| Settlement Date (T+8*) | December 1, 2026 |
| Maturity Date | December 1, 2028 |
| Price to Public | 100.000% of the principal amount |
| Index | Three-month EURIBOR, as described under "Description of the Notes - Floating Rate Notes" in the preliminary prospectus supplement |
| Interest Rate | Applicable EURIBOR Rate plus 63 basis points per annum |
| Minimum Interest Rate | 0.000% per annum |
| Maximum Interest Rate | As permitted by New York law |
| Floating Rate Interest Reset Dates | March 1, June 1, September 1 and December 1 of each year; initial Floating Rate Interest Reset Date of December 1, 2026 |
| Interest Determination Date | Two T2 days preceding each Floating Rate Interest Reset Date |
| Spread to EURIBOR | Plus 63 basis points |
* It is expected that delivery of the notes will be made to purchasers on or about December 1, 2026, which is the eighth business day following the date of pricing of the notes (such settlement cycle referred to as T+8), through Clearstream Banking S.A. and Euroclear Bank SA/NV. Under Rule 15c6-1 under the Securities Exchange Act of 1934, as amended, trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the notes on any date prior to the business day before delivery of the notes will be required, by virtue of the fact that the notes will settle in T+8, to specify an alternative settlement cycle at the time of any such trade to prevent a failed settlement; such purchasers should consult their own advisors in this regard.
| Interest Payment Dates | Quarterly in arrears on March 1, June 1, September 1 and December 1 of each year, beginning March 1, 2027 |
| EURIBOR Business Day | Any day that is not a Saturday or Sunday and that, in the City of New York or the City of London, is not a day on which banking institutions are generally authorized or obligated by law to close, and is a day on which the T2 System, or any successor thereto, operates |
| Business Day Convention | Modified following, adjusted (Floating Rate Interest Reset Dates and Floating Rate Interest Payment Dates); following, unadjusted (Maturity Date and any redemption date) |
| Calculation Agent | U.S. Bank Europe DAC |
| Optional Redemption | Except in connection with certain tax events, the Floating Rate Notes are not redeemable prior to maturity |
| Stabilization | Stabilization/FCA |
| Day Count Basis | Actual/360 |
| Minimum Denominations | €100,000 and integral multiples of €1,000 in excess thereof |
| Common Code / ISIN |
Common Code: 357749905 ISIN: XS3577499059 |
| Clearing and Settlement | Clearstream Banking S.A. / Euroclear Bank SA/NV |
| Trustee | U.S. Bank Trust Company, National Association |
| Registrar and Paying Agent | U.S. Bank Europe DAC |
| Expected Listing | Application will be made to list the notes on the Official List of the Irish Stock Exchange plc for trading as Euronext Dublin and to admit the notes to trading on the Global Exchange Market thereof |
| Joint Bookrunners |
Barclays Bank PLC Citigroup Global Markets Europe AG J.P. Morgan SE BofA Securities Europe SA Morgan Stanley & Co. International plc Wells Fargo Securities Europe, S.A. |
| Co-Managers |
BNP PARIBAS Deutsche Bank Aktiengesellschaft Goldman Sachs & Co. LLC RBC Europe Limited Scotiabank (Ireland) Designated Activity Company Société Générale Standard Chartered Bank TD Global Finance unlimited company |
| Stabilization Manager | Barclays Bank PLC |
| Use of Proceeds | We intend to use the net proceeds from this offering, together with any net proceeds of the USD Notes offering, short-term borrowings and/or borrowings under our credit agreement(s) and cash on hand, to finance the cash consideration payable in connection with the Penumbra Acquisition and to pay related fees and expenses and, to the extent that the net proceeds from this offering are not used for such purposes, for general corporate purposes, which may include, among other things, short term investments, reduction of short term debt, funding of working capital and potential future acquisitions. |
| Concurrent Offering | Substantially concurrently with this offering, Boston Scientific intends to offer, by means of a separate prospectus supplement, dollar-denominated notes (the "USD Notes"). The completion of the USD Notes offering is not a condition to the completion of this offering. |
| Special Mandatory Redemption | Not applicable. |
Terms and Conditions - 2-YearFixed Rate Notes (the "2028 Notes")
| Issuer | American Medical Systems Europe B.V. (the "Issuer") |
| Guarantor | Boston Scientific Corporation ("Boston Scientific") |
| Note Type | Senior Notes |
| Form of Offering | SEC Registered |
|
Issuer Ratings (M/S&P/F)1 |
A3 / A- / A- (Negative/Negative/Stable) |
|
Expected Ratings (M/S&P/F) |
A3 / A- / A- |
| Principal Amount | €500,000,000 |
| Trade Date | November 19, 2026 |
| Settlement Date (T+8*) | December 1, 2026 |
| Maturity Date | December 1, 2028 |
| Coupon | 3.875% per annum |
| Yield to Maturity | 3.944% per annum |
| Price to Public | 99.870% of the principal amount |
| Reference to Mid-Swaps Rate | 3.414% |
| Spread to Mid-Swaps Rate | Plus 53 basis points |
| Benchmark Bund | OBL 2.400% due October 19, 2028 |
| Spread to Benchmark Bund | Plus 74.6 basis points |
| Benchmark Bund Yield/Price | 3.198% / €98.545 |
| Interest Payment Dates | Annually on December 1, beginning December 1, 2027 |
| Par Call Date | Not applicable. |
| Make-whole Call | Plus 15 basis points |
* It is expected that delivery of the notes will be made to purchasers on or about December 1, 2026, which is the eighth business day following the date of pricing of the notes (such settlement cycle referred to as T+8), through Clearstream Banking S.A. and Euroclear Bank SA/NV. Under Rule 15c6-1 under the Securities Exchange Act of 1934, as amended, trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the notes on any date prior to the business day before delivery of the notes will be required, by virtue of the fact that the notes will settle in T+8, to specify an alternative settlement cycle at the time of any such trade to prevent a failed settlement; such purchasers should consult their own advisors in this regard.
| Stabilization | Stabilization/FCA |
| Day Count Basis | ACTUAL/ACTUAL (ICMA) |
| Minimum Denominations | €100,000 and integral multiples of €1,000 in excess thereof |
| Common Code / ISIN |
Common Code: 357300738 ISIN: XS3573007385 |
| Clearing and Settlement | Clearstream Banking S.A. / Euroclear Bank SA/NV |
| Trustee | U.S. Bank Trust Company, National Association |
| Registrar and Paying Agent | U.S. Bank Europe DAC |
| Expected Listing | Application will be made to list the notes on the Official List of the Irish Stock Exchange plc for trading as Euronext Dublin and to admit the notes to trading on the Global Exchange Market thereof |
| Joint Bookrunners |
Barclays Bank PLC Citigroup Global Markets Europe AG J.P. Morgan SE BofA Securities Europe SA Morgan Stanley & Co. International plc Wells Fargo Securities Europe, S.A. |
| Co-Managers |
BNP PARIBAS Deutsche Bank Aktiengesellschaft Goldman Sachs & Co. LLC RBC Europe Limited Scotiabank (Ireland) Designated Activity Company Société Générale Standard Chartered Bank TD Global Finance unlimited company |
| Stabilization Manager | Barclays Bank PLC |
| Use of Proceeds | We intend to use the net proceeds from this offering, together with any net proceeds of the USD Notes offering, short-term borrowings and/or borrowings under our credit agreement(s) and cash on hand, to finance the cash consideration payable in connection with the Penumbra Acquisition and to pay related fees and expenses and, to the extent that the net proceeds from this offering are not used for such purposes, for general corporate purposes, which may include, among other things, short term investments, reduction of short term debt, funding of working capital and potential future acquisitions. |
| Concurrent Offering | Substantially concurrently with this offering, Boston Scientific intends to offer, by means of a separate prospectus supplement, dollar-denominated notes (the "USD Notes"). The completion of the USD Notes offering is not a condition to the completion of this offering. |
| Special Mandatory Redemption | If (i) the Penumbra Acquisition is not completed on or before the Special Mandatory Redemption End Date or (ii) AMS Europe notifies the trustee under the indenture and the paying agent that Boston Scientific will not pursue completion of the Penumbra Acquisition, AMS Europe will be required to redeem the 2028 Notes at a special mandatory redemption price equal to 101% of the aggregate principal amount of the 2028 Notes, plus accrued and unpaid interest, if any, to, but excluding, the Special Mandatory Redemption Date. |
Terms and Conditions - 4-YearFixed Rate Notes (the "2030 Notes")
| Issuer | American Medical Systems Europe B.V. (the "Issuer") |
| Guarantor | Boston Scientific Corporation ("Boston Scientific") |
| Note Type | Senior Notes |
| Form of Offering | SEC Registered |
|
Issuer Ratings (M/S&P/F)1 |
A3 / A- / A- (Negative/Negative/Stable) |
|
Expected Ratings (M/S&P/F)1 |
A3 / A- / A- |
| Principal Amount | €750,000,000 |
| Trade Date | November 19, 2026 |
| Settlement Date (T+8*) | December 1, 2026 |
| Maturity Date | December 1, 2030 |
| Coupon | 4.125% per annum |
| Yield to Maturity | 4.166% per annum |
| Price to Public | 99.852% of the principal amount |
| Reference to Mid-Swaps Rate | 3.416% |
| Spread to Mid-Swaps Rate | Plus 75 basis points |
| Benchmark Bund | OBL 2.200% due October 10, 2030 |
| Spread to Benchmark Bund | Plus 96.3 basis points |
| Benchmark Bund Yield/Price | 3.203% / €96.390 |
| Interest Payment Dates | Annually on December 1, beginning December 1, 2027 |
| Par Call Date | On or after November 1, 2030 (the date that is one month prior to the maturity date) |
| Make-whole Call | Plus 15 basis points |
* It is expected that delivery of the notes will be made to purchasers on or about December 1, 2026, which is the eighth business day following the date of pricing of the notes (such settlement cycle referred to as T+8), through Clearstream Banking S.A. and Euroclear Bank SA/NV. Under Rule 15c6-1 under the Securities Exchange Act of 1934, as amended, trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the notes on any date prior to the business day before delivery of the notes will be required, by virtue of the fact that the notes will settle in T+8, to specify an alternative settlement cycle at the time of any such trade to prevent a failed settlement; such purchasers should consult their own advisors in this regard.
| Stabilization | Stabilization/FCA |
| Day Count Basis | ACTUAL/ACTUAL (ICMA) |
| Minimum Denominations | €100,000 and integral multiples of €1,000 in excess thereof |
| Common Code / ISIN |
Common Code: 357300860 ISIN: XS3573008607 |
| Clearing and Settlement | Clearstream Banking S.A. / Euroclear Bank SA/NV |
| Trustee | U.S. Bank Trust Company, National Association |
| Registrar and Paying Agent | U.S. Bank Europe DAC |
| Expected Listing | Application will be made to list the notes on the Official List of the Irish Stock Exchange plc for trading as Euronext Dublin and to admit the notes to trading on the Global Exchange Market thereof |
| Joint Bookrunners |
Barclays Bank PLC Citigroup Global Markets Europe AG J.P. Morgan SE BofA Securities Europe SA Morgan Stanley & Co. International plc Wells Fargo Securities Europe, S.A. |
| Co-Managers |
BNP PARIBAS Deutsche Bank Aktiengesellschaft Goldman Sachs & Co. LLC RBC Europe Limited Scotiabank (Ireland) Designated Activity Company Société Générale Standard Chartered Bank TD Global Finance unlimited company |
| Stabilization Manager | Barclays Bank PLC |
| Use of Proceeds | We intend to use the net proceeds from this offering, together with any net proceeds of the USD Notes offering, short-term borrowings and/or borrowings under our credit agreement(s) and cash on hand, to finance the cash consideration payable in connection with the Penumbra Acquisition and to pay related fees and expenses and, to the extent that the net proceeds from this offering are not used for such purposes, for general corporate purposes, which may include, among other things, short term investments, reduction of short term debt, funding of working capital and potential future acquisitions. |
| Concurrent Offering | Substantially concurrently with this offering, Boston Scientific intends to offer, by means of a separate prospectus supplement, dollar-denominated notes (the "USD Notes"). The completion of the USD Notes offering is not a condition to the completion of this offering. |
| Special Mandatory Redemption | If (i) the Penumbra Acquisition is not completed on or before the Special Mandatory Redemption End Date or (ii) AMS Europe notifies the trustee under the indenture and the paying agent that Boston Scientific will not pursue completion of the Penumbra Acquisition, AMS Europe will be required to redeem the 2030 Notes at a special mandatory redemption price equal to 101% of the aggregate principal amount of the 2030 Notes, plus accrued and unpaid interest, if any, to, but excluding, the Special Mandatory Redemption Date. |
Terms and Conditions - 8-YearFixed Rate Notes (the "2034 Notes")
| Issuer | American Medical Systems Europe B.V. (the "Issuer") |
| Guarantor | Boston Scientific Corporation ("Boston Scientific") |
| Note Type | Senior Notes |
| Form of Offering | SEC Registered |
|
Issuer Ratings (M/S&P/F)1 |
A3 / A- / A- (Negative/Negative/Stable) |
|
Expected Ratings (M/S&P/F)1 |
A3 / A- / A- |
| Principal Amount | €750,000,000 |
| Trade Date | November 19, 2026 |
| Settlement Date (T+8*) | December 1, 2026 |
| Maturity Date | December 1, 2034 |
| Coupon | 4.500% per annum |
| Yield to Maturity | 4.525% per annum |
| Price to Public | 99.835% of the principal amount |
| Reference to Mid-Swaps Rate | 3.425% |
| Spread to Mid-Swaps Rate | Plus 110 basis points |
| Benchmark Bund | DBR 2.600% due August 15, 2034 |
| Spread to Benchmark Bund | Plus 120.0 basis points |
| Benchmark Bund Yield/Price | 3.325% / €95.120 |
| Interest Payment Dates | Annually on December 1, beginning December 1, 2027 |
| Par Call Date | On or after September 1, 2034 (the date that is three months prior to the maturity date) |
| Make-whole Call | Plus 20 basis points |
* It is expected that delivery of the notes will be made to purchasers on or about December 1, 2026, which is the eighth business day following the date of pricing of the notes (such settlement cycle referred to as T+8), through Clearstream Banking S.A. and Euroclear Bank SA/NV. Under Rule 15c6-1 under the Securities Exchange Act of 1934, as amended, trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the notes on any date prior to the business day before delivery of the notes will be required, by virtue of the fact that the notes will settle in T+8, to specify an alternative settlement cycle at the time of any such trade to prevent a failed settlement; such purchasers should consult their own advisors in this regard.
| Stabilization | Stabilization/FCA |
| Day Count Basis | ACTUAL/ACTUAL (ICMA) |
| Minimum Denominations | €100,000 and integral multiples of €1,000 in excess thereof |
| Common Code / ISIN |
Common Code: 357300886 ISIN: XS3573008862 |
| Clearing and Settlement | Clearstream Banking S.A. / Euroclear Bank SA/NV |
| Trustee | U.S. Bank Trust Company, National Association |
| Registrar and Paying Agent | U.S. Bank Europe DAC |
| Expected Listing | Application will be made to list the notes on the Official List of the Irish Stock Exchange plc for trading as Euronext Dublin and to admit the notes to trading on the Global Exchange Market thereof |
| Joint Bookrunners |
Barclays Bank PLC Citigroup Global Markets Europe AG J.P. Morgan SE BofA Securities Europe SA Morgan Stanley & Co. International plc Wells Fargo Securities Europe, S.A. |
| Co-Managers |
BNP PARIBAS Deutsche Bank Aktiengesellschaft Goldman Sachs & Co. LLC RBC Europe Limited Scotiabank (Ireland) Designated Activity Company Société Générale Standard Chartered Bank TD Global Finance unlimited company |
| Stabilization Manager | Barclays Bank PLC |
| Use of Proceeds | We intend to use the net proceeds from this offering, together with any net proceeds of the USD Notes offering, short-term borrowings and/or borrowings under our credit agreement(s) and cash on hand, to finance the cash consideration payable in connection with the Penumbra Acquisition and to pay related fees and expenses and, to the extent that the net proceeds from this offering are not used for such purposes, for general corporate purposes, which may include, among other things, short term investments, reduction of short term debt, funding of working capital and potential future acquisitions. |
| Concurrent Offering | Substantially concurrently with this offering, Boston Scientific intends to offer, by means of a separate prospectus supplement, dollar-denominated notes (the "USD Notes"). The completion of the USD Notes offering is not a condition to the completion of this offering. |
| Special Mandatory Redemption | If (i) the Penumbra Acquisition is not completed on or before the Special Mandatory Redemption End Date or (ii) AMS Europe notifies the trustee under the indenture and the paying agent that Boston Scientific will not pursue completion of the Penumbra Acquisition, AMS Europe will be required to redeem the 2034 Notes at a special mandatory redemption price equal to 101% of the aggregate principal amount of the 2034 Notes, plus accrued and unpaid interest, if any, to, but excluding, the Special Mandatory Redemption Date. |
Terms and Conditions - 12-YearFixed Rate Notes (the "2038 Notes")
| Issuer | American Medical Systems Europe B.V. (the "Issuer") |
| Guarantor | Boston Scientific Corporation ("Boston Scientific") |
| Note Type | Senior Notes |
| Form of Offering | SEC Registered |
|
Issuer Ratings (M/S&P/F)1 |
A3 / A- / A- (Negative/Negative/Stable) |
|
Expected Ratings (M/S&P/F)1 |
A3 / A- / A- |
| Principal Amount | €1,000,000,000 |
| Trade Date | November 19, 2026 |
| Settlement Date (T+8*) | December 1, 2026 |
| Maturity Date | December 1, 2038 |
| Coupon | 4.750% per annum |
| Yield to Maturity | 4.831% per annum |
| Price to Public | 99.275% of the principal amount |
| Reference to Mid-Swaps Rate | 3.481% |
| Spread to Mid-Swaps Rate | Plus 135 basis points |
| Benchmark Bund | DBR 1.000% due May 15, 2038 |
| Spread to Benchmark Bund | Plus 130.6 basis points |
| Benchmark Bund Yield/Price | 3.525% / €76.500 |
| Interest Payment Dates | Annually on December 1, beginning December 1, 2027 |
| Par Call Date | On or after September 1, 2038 (the date that is three months prior to the maturity date) |
| Make-whole Call | Plus 20 basis points |
* It is expected that delivery of the notes will be made to purchasers on or about December 1, 2026, which is the eighth business day following the date of pricing of the notes (such settlement cycle referred to as T+8), through Clearstream Banking S.A. and Euroclear Bank SA/NV. Under Rule 15c6-1 under the Securities Exchange Act of 1934, as amended, trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the notes on any date prior to the business day before delivery of the notes will be required, by virtue of the fact that the notes will settle in T+8, to specify an alternative settlement cycle at the time of any such trade to prevent a failed settlement; such purchasers should consult their own advisors in this regard.
| Stabilization | Stabilization/FCA |
| Day Count Basis | ACTUAL/ACTUAL (ICMA) |
| Minimum Denominations | €100,000 and integral multiples of €1,000 in excess thereof |
| Common Code / ISIN |
Common Code: 357300916 ISIN: XS3573009167 |
| Clearing and Settlement | Clearstream Banking S.A. / Euroclear Bank SA/NV |
| Trustee | U.S. Bank Trust Company, National Association |
| Registrar and Paying Agent | U.S. Bank Europe DAC |
| Expected Listing | Application will be made to list the notes on the Official List of the Irish Stock Exchange plc for trading as Euronext Dublin and to admit the notes to trading on the Global Exchange Market thereof |
| Joint Bookrunners |
Barclays Bank PLC Citigroup Global Markets Europe AG J.P. Morgan SE BofA Securities Europe SA Morgan Stanley & Co. International plc Wells Fargo Securities Europe, S.A. |
| Co-Managers |
BNP PARIBAS Deutsche Bank Aktiengesellschaft Goldman Sachs & Co. LLC RBC Europe Limited Scotiabank (Ireland) Designated Activity Company Société Générale Standard Chartered Bank TD Global Finance unlimited company |
| Stabilization Manager | Barclays Bank PLC |
| Use of Proceeds | We intend to use the net proceeds from this offering, together with any net proceeds of the USD Notes offering, short-term borrowings and/or borrowings under our credit agreement(s) and cash on hand, to finance the cash consideration payable in connection with the Penumbra Acquisition and to pay related fees and expenses and, to the extent that the net proceeds from this offering are not used for such purposes, for general corporate purposes, which may include, among other things, short term investments, reduction of short term debt, funding of working capital and potential future acquisitions. |
| Concurrent Offering | Substantially concurrently with this offering, Boston Scientific intends to offer, by means of a separate prospectus supplement, dollar-denominated notes (the "USD Notes"). The completion of the USD Notes offering is not a condition to the completion of this offering. |
| Special Mandatory Redemption | If (i) the Penumbra Acquisition is not completed on or before the Special Mandatory Redemption End Date or (ii) AMS Europe notifies the trustee under the indenture and the paying agent that Boston Scientific will not pursue completion of the Penumbra Acquisition, AMS Europe will be required to redeem the 2038 Notes at a special mandatory redemption price equal to 101% of the aggregate principal amount of the 2038 Notes, plus accrued and unpaid interest, if any, to, but excluding, the Special Mandatory Redemption Date. |
Terms and Conditions - 20-YearFixed Rate Notes (the "2046 Notes")
| Issuer | American Medical Systems Europe B.V. (the "Issuer") |
| Guarantor | Boston Scientific Corporation ("Boston Scientific") |
| Note Type | Senior Notes |
| Form of Offering | SEC Registered |
|
Issuer Ratings (M/S&P/F)1 |
A3 / A- / A- (Negative/Negative/Stable) |
|
Expected Ratings (M/S&P/F) |
A3 / A- / A- |
| Principal Amount | €750,000,000 |
| Trade Date | November 19, 2026 |
| Settlement Date (T+8*) | December 1, 2026 |
| Maturity Date | December 1, 2046 |
| Coupon | 5.125% per annum |
| Yield to Maturity | 5.182% per annum |
| Price to Public | 99.300% of the principal amount |
| Reference to Mid-Swaps Rate | 3.482% |
| Spread to Mid-Swaps Rate | Plus 170 basis points |
| Benchmark Bund | DBR 2.500% due August 15, 2046 |
| Spread to Benchmark Bund | Plus 143.3 basis points |
| Benchmark Bund Yield/Price | 3.749% / €82.790 |
| Interest Payment Dates | Annually on December 1, beginning December 1, 2027 |
| Par Call Date | On or after June 1, 2046 (the date that is six months prior to the maturity date) |
| Make-whole Call | Plus 25 basis points |
* It is expected that delivery of the notes will be made to purchasers on or about December 1, 2026, which is the eighth business day following the date of pricing of the notes (such settlement cycle referred to as T+8), through Clearstream Banking S.A. and Euroclear Bank SA/NV. Under Rule 15c6-1 under the Securities Exchange Act of 1934, as amended, trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the notes on any date prior to the business day before delivery of the notes will be required, by virtue of the fact that the notes will settle in T+8, to specify an alternative settlement cycle at the time of any such trade to prevent a failed settlement; such purchasers should consult their own advisors in this regard.
| Stabilization | Stabilization/FCA |
| Day Count Basis | ACTUAL/ACTUAL (ICMA) |
| Minimum Denominations | €100,000 and integral multiples of €1,000 in excess thereof |
| Common Code / ISIN |
Common Code: 357300967 ISIN: XS3573009670 |
| Clearing and Settlement | Clearstream Banking S.A. / Euroclear Bank SA/NV |
| Trustee | U.S. Bank Trust Company, National Association |
| Registrar and Paying Agent | U.S. Bank Europe DAC |
| Expected Listing | Application will be made to list the notes on the Official List of the Irish Stock Exchange plc for trading as Euronext Dublin and to admit the notes to trading on the Global Exchange Market thereof |
| Joint Bookrunners |
Barclays Bank PLC Citigroup Global Markets Europe AG J.P. Morgan SE BofA Securities Europe SA Morgan Stanley & Co. International plc Wells Fargo Securities Europe, S.A. |
| Co-Managers |
BNP PARIBAS Deutsche Bank Aktiengesellschaft Goldman Sachs & Co. LLC RBC Europe Limited Scotiabank (Ireland) Designated Activity Company Société Générale Standard Chartered Bank TD Global Finance unlimited company |
| Stabilization Manager | Barclays Bank PLC |
| Use of Proceeds | We intend to use the net proceeds from this offering, together with any net proceeds of the USD Notes offering, short-term borrowings and/or borrowings under our credit agreement(s) and cash on hand, to finance the cash consideration payable in connection with the Penumbra Acquisition and to pay related fees and expenses and, to the extent that the net proceeds from this offering are not used for such purposes, for general corporate purposes, which may include, among other things, short term investments, reduction of short term debt, funding of working capital and potential future acquisitions. |
| Concurrent Offering | Substantially concurrently with this offering, Boston Scientific intends to offer, by means of a separate prospectus supplement, dollar-denominated notes (the "USD Notes"). The completion of the USD Notes offering is not a condition to the completion of this offering. |
| Special Mandatory Redemption | If (i) the Penumbra Acquisition is not completed on or before the Special Mandatory Redemption End Date or (ii) AMS Europe notifies the trustee under the indenture and the paying agent that Boston Scientific will not pursue completion of the Penumbra Acquisition, AMS Europe will be required to redeem the 2046 Notes at a special mandatory redemption price equal to 101% of the aggregate principal amount of the 2046 Notes, plus accrued and unpaid interest, if any, to, but excluding, the Special Mandatory Redemption Date. |
Note:
| 1 | A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time. |
MiFID II and UK MiFIR - professionals/ECPs-only / No EEA PRIIPs KID or UK PRIIPs KID/CCI product summary - Manufacturer target market (MiFID II and UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels). No EEA PRIIPs key information document (KID) or UK PRIIPs KID/CCI product summary has been prepared as not available to retail in EEA or UK.
The Issuer has filed a registration statement (including a preliminary prospectus supplement dated November 19, 2026 (the "preliminary prospectus supplement") and accompanying prospectus dated February 18, 2025 (the "base prospectus" and together with the preliminary prospectus supplement, the "preliminary prospectus") with the U.S. Securities and Exchange Commission (the "SEC") for the offering to which this communication relates. Before you invest, you should read the preliminary prospectus supplement and accompanying prospectus and other documents the Issuer has filed with the SEC for more complete information about the Issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the Issuer, any underwriter or any dealer participating in the offering will arrange to send you the preliminary prospectus supplement and accompanying prospectus if you request it by calling Barclays Bank PLC toll-free at 1-888-603-5847, Citigroup Global Markets Europe AG toll-free at 1-800-831-9146 or J.P. Morgan SE toll-free at +49 69 71240 (non-U.S. investors) or J.P. Morgan Securities LLC collect at 1-212-834-4533 (U.S. investors).
Capitalized terms used but not defined herein have the meanings assigned to them in the preliminary prospectus supplement.
Any disclaimers or other notices that may appear below are not applicable to this communication and should be disregarded. Such disclaimers or other notices were automatically generated as a result of this communication being sent via Bloomberg or another email system.